Different prognosis for stage IIB cervical cancer patients with unilateral or bilateral parametrial invasion treated with concurrent chemoradiotherapy
Rattachement africain : cn, hk. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: To compare the survival difference between 2018 International Federation of Gynecology and Obstetrics (FIGO) stage IIB cervical cancer (CC) patients with unilateral parametrial invasion (UL) and bilateral parametrial invasion (BL) disease, and explore the significant role of parametrial invasion (PI) in prognosis prediction. METHODS: A total of 506 stage IIB CC patients were identified from the multi-center study, and patients were divided into UL and BL groups according to gynecological and radiological examination. Survival outcomes were estimated and compared between 2 groups before and after propensity scoring matching (PSM). The role of upper 2/3 vaginal invasion (VI) in impacting survival probability was also assessed. The random forest (RF) model was constructed and validated to select important features related to survival outcomes and predict prognosis for these patients. The SHapley Additive exPlanation (SHAP) was further introduced to provide a better understanding toward the findings from the RF model. RESULTS: Significant better 5-year overall survival (OS) was observed among patients with UL disease whether before (BL: 61.7% [95% CI: 57.0%-66.4%]; UL: 84.8% [95% CI: 82.4%-87.2%]; HR = 2.83, 95% CI: 1.90-4.20, P < 0.001) or after PSM (BL: 61.3% [95% CI: 56.6%-66.0%]; UL: 81.2% [95% CI: 77.3%-85.1%]; HR = 2.51, 95% CI: 1.56-4.04, P < 0.001). Similar findings could also be observed in terms of progression-free survival (PFS). The presence of VI didn't significantly impair the survival probability, whether in the UL or BL group (all P > 0.05). RF model was constructed, which possessed decent predictive ability both in the training (area under the receiver operating characteristic curve [AUC] = 0.893; 95% CI: 0.874-0.912) and validation cohort (AUC = 0.879; 95% CI: 0.801-0.957). PI was identified to be the paramount feature in affecting the survival outcomes for stage IIB CC patients through the Beeswarm summary plot and bar chart in SHAP analysis. CONCLUSION: Our findings demonstrated that 2018 FIGO stage IIB CC patients with BL disease had a worse prognosis than those with UL disease, and PI was the most significant feature in prognosis prediction for these patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Different prognosis for stage IIB cervical cancer patients with unilateral or bilateral parametrial invasion treated with concurrent chemoradiotherapy
- Date Crossref
- 16/10/2025
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Chinese Academy of Medical Sciences & Peking Union Medical College pays non établi dans la noticeUniversité ou école supérieure
-
Peking Union Medical College Hospital Department of Radiation Oncology pays non établi dans la noticeÉtablissement de santé
-
Xijing Hospital pays non établi dans la noticeÉtablissement de santé
-
Ningxia Medical University Department of Radiation Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Ningxia Medical University General Hospital pays non établi dans la noticeÉtablissement de santé
-
Second Affiliated Hospital of Jilin University Department of Radiation Oncology pays non établi dans la noticeÉtablissement de santé
-
Guiyang Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Guizhou Cancer Hospital pays non établi dans la noticeÉtablissement de santé
-
Affiliated Hospital of Guizhou Medical University pays non établi dans la noticeÉtablissement de santé
-
Dalian Medical University Department of Radiation Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Second Affiliated Hospital of Dalian Medical University pays non établi dans la noticeÉtablissement de santé
-
Inner Mongolia Medical University Department of Radiation Oncology pays non établi dans la noticeOrganisme public
Chinese Academy of Medical Sciences & Peking Union Medical College, Department of Radiation Oncology — Peking Union Medical College Hospital et Xijing Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.